TRECX acquires majority stake in Ecuador’s Pharmavida

TRECX is part of the Pintulac Group, one of Ecuador’s most prominent and diversified business groups, recognized for its nationwide presence and leadership in the distribution of industrial, construction, and specialty products. With more than 60 years of experience and a strong focus on innovation, operational excellence, and responsible growth, TRECX continues to expand its portfolio into new strategic sectors.

The transaction marks a significant strategic expansion for the Pintulac Group into the healthcare and pharmaceutical sectors, according to Ecuadorian law firm Bustamante Fabara, which advised TRECX on the acquisition.

The transaction was structured through a share purchase agreement combining an upfront payment to the seller with a capitalization contribution to the company, along with an additional capital injection to be completed within a defined period. This structure not only secures majority control for the shareholder-owners of TRECX, but also strengthens the company’s working capital and supports its medium-term operational growth.

Bustamante Fabara conducted a comprehensive due diligence review of the target, assessing its corporate, regulatory, contractual, and financial standing. The team also led the preparation and negotiation of all core transaction documents, including the share purchase agreement, the non-disclosure agreement, the shareholders’ agreement and the corresponding bylaws reform to reflect the new ownership structure and governance framework.

The law firm’s team advising the shareholder-owners of TRECX was led by managing partner María Rosa Fabara Vera, together with director Andrés Becdach and senior associate Adriana Lasso, along with other attorneys specializing in corporate and regulatory matters.

Bustamante Fabara is one of Ecuador’s leading law firms, with a strong track record advising on complex financial transactions, cross-border deals, and international projects, with over 120 lawyers and 190 total team members.